Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Nicholas C. Turner et al.|Annals of Oncology|2021Cited by 1.4k
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C. Coombs, Michael F. Berger, Ahmet Zehir et al.|Cell stem cell|2017Cited by 851
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L. Bolton, Dean F. Bajorin, Ryan Ptashkin et al.|Nature Genetics|2020Cited by 739
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingWassim Abida, Howard I. Scher, Joshua Armenia et al.|JCO Precision Oncology|2017Cited by 529